AI News

    Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion

    Eli Lilly bets big on generative AI to revolutionize the next generation of precision medicine.

    Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion Bloomberg.com

    BT

    Bloomberg Technology

    Source

    Bloomberg Technology
    AI Analysis

    Generated insight by OnAirToday AI

    This massive partnership signals a pivotal shift as pharmaceutical giants increasingly rely on generative protein design to accelerate complex drug discovery. By integrating Profluent's AI models, Lilly aims to drastically reduce the traditional timeline for developing therapeutic protein candidates.

    Powered by AI • Not a substitute for human analysisMore Insights →
    Read the full story at Bloomberg Technology →
    Share
    Filed under:AI News

    Comments

    Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.

    0/1000